These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24107972)

  • 21. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.
    Clevenger L; Schrepf A; Degeest K; Bender D; Goodheart M; Ahmed A; Dahmoush L; Penedo F; Lucci J; Thaker PH; Mendez L; Sood AK; Slavich GM; Lutgendorf SK
    Cancer; 2013 Sep; 119(17):3234-41. PubMed ID: 23797955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
    Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
    Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
    Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
    Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
    Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
    [No Abstract]   [Full Text] [Related]  

  • 26. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer.
    Xu X; Chen X; Dai Z; Deng F; Qu J; Ni J
    J Exp Clin Cancer Res; 2013 Sep; 32(1):61. PubMed ID: 24059600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features of long-term survivors of recurrent epithelial ovarian cancer.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Sakamoto K; Takizawa K; Takeshima N
    Int J Clin Oncol; 2015 Feb; 20(1):143-9. PubMed ID: 24664306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
    Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
    Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of epithelial ovarian cancer diagnosis on women's life: a qualitative study.
    Mangone L; Mandato VD; Gandolfi R; Tromellini C; Abrate M
    Eur J Gynaecol Oncol; 2014; 35(1):32-8. PubMed ID: 24654458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral cyclophosphamide in recurrent ovarian cancer.
    Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.
    Friedlander M; Butow P; Stockler M; Gainford C; Martyn J; Oza A; Donovan HS; Miller B; King M
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S44-8. PubMed ID: 19955914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
    Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
    BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
    Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML
    Gynecol Oncol; 2020 Jan; 156(1):45-53. PubMed ID: 31836184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and its associated psychological variables of symptoms of depression and anxiety among ovarian cancer patients in China: a cross-sectional study.
    Liu CL; Liu L; Zhang Y; Dai XZ; Wu H
    Health Qual Life Outcomes; 2017 Aug; 15(1):161. PubMed ID: 28818112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.